SCHEMBL1060735

SCHEMBL1060735

Cn1nnc(-c2ccc(OCc3ccccc3)c(F)c2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.54
RAB9A P51151 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
TSHR P16473 3/20 0.54
MAPT P10636 3/20 0.54
MAOB P27338 2/20 0.46
ERN1 O75460 1/20 0.45
GRM2 Q14416 1/20 0.43
ACLY P53396 1/20 0.42
USP2 O75604 2/20 0.41
TP53 P04637 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
BRD4 O60885 1/20 0.41
S1PR5 Q9H228 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1055385 0.83 NPC1 (0.53) NPC1RAB9ASMN1; SMN2TSHRMAPT
SCHEMBL1058756 0.80 NPC1 (0.52) NPC1RAB9ASMN1; SMN2TSHRMAPT
SCHEMBL8807192 0.79 MAOB (0.70) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL1059430 0.78 ALDH1A1 (0.51) NPC1RAB9ASMN1; SMN2TSHRMAPT
SCHEMBL31605147 0.77 NPC1 (0.50) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL31605138 0.77 NPC1 (0.50) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL7793991 0.76 XDH (0.53) ERN1MRGPRX4S1PR5
SCHEMBL31086482 0.75 MRGPRX4 (0.56) MAPTMRGPRX4KDM4CALDH1A1LMNA
SCHEMBL1055134 0.75 MRGPRX4 (0.56) MAPTMRGPRX4KDM4CALDH1A1LMNA
SCHEMBL8993289 0.75 ERN1 (0.57) MAPTERN1GRM2MRGPRX4S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459222-B L- (piperidin-4-yl) -pyrazole derivatives as GPR119 modulators PFIZER 2014-06-04 CN disclosed
EP-2643310-A1 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS Pfizer Inc (US) 2013-10-02 EP disclosed
CN-103298801-A 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as GPR 119 modulators PFIZER 2013-09-11 CN disclosed
WO-2012069948-A1 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS PFIZER INC. (US) 2012-05-31 WO disclosed
CN-102459222-A L- (piperidin-4-yl) -pyrazole derivatives as GPR119 modulators PFIZER 2012-05-16 CN disclosed
EP-2438051-A1 L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS Pfizer Inc. (US) 2012-04-11 EP disclosed
US-20110020460-A1 GPR 119 MODULATORS PFIZER INC. 2011-01-27 US disclosed
WO-2010140092-A1 L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS PFIZER INC. (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110020460-A1 GPR 119 MODULATORS GPR119, GPR65, GPR88 NPC1 626/4885RAB9A 534/4885SMN1; SMN2 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.